Form 13-F position report

KINIKSA PHARMACEUTICALS INTL

Reported by RICE HALL JAMES & ASSOCIATES LLC

KNSA CUSIP G52694109 Manager CIK 0001230765

Reported 466,050 shares, down 158,878 (25.4%) from the prior quarter.

Reported value -13.0%; share count -25.4% vs. the prior quarter.

Reduced
% of reported 13F value 1.84% This manager · Q3 2026
Shares 466,050 Quarter-end amount reported
Reported value $34,771,991 Fair value at quarter end
Consecutive quarters held 10 Through Q3 2026

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2024-06-30 11213762
2024-09-30 16234254
2024-12-31 12713642
2025-03-31 13871144
2025-06-30 17659907
2025-09-30 22436828
2025-12-31 24602779
2026-03-31 29295230
2026-06-30 39964146
2026-09-30 34771991

Quarterly position history

How this manager's reported quarter-end position changed over time.

10 quarters
Quarterly reported position history for KINIKSA PHARMACEUTICALS INTL held by RICE HALL JAMES & ASSOCIATES LLC.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q3 2026 Reduced 466,050 -158,878 (-25.4%) 1.84% $34,771,991 2026-11-16
Q2 2026 Added 624,928 +16,512 (2.7%) 1.95% $39,964,146 2026-08-07
Q1 2026 Added 608,416 +11,985 (2.0%) 1.63% $29,295,230 2026-05-15
Q4 2025 Added 596,431 +18,609 (3.2%) 1.35% $24,602,779 2026-02-17
Q3 2025 Reduced 577,822 -60,411 (-9.5%) 1.22% $22,436,828 2025-10-16
Q2 2025 Added 638,233 +13,688 (2.2%) 0.95% $17,659,907 2025-08-11
Q1 2025 Reduced 624,545 -18,207 (-2.8%) 0.82% $13,871,144 2025-05-01
Q4 2024 Reduced 642,752 -6,878 (-1.1%) 0.7% $12,713,642 2025-01-31
Q3 2024 Added 649,630 +49,000 (8.2%) 0.88% $16,234,254 2024-10-28
Q2 2024 New 600,630 +600,630 (0.0%) 0.67% $11,213,762 2024-08-07

Who else reported the position

328 managers reported KINIKSA PHARMACEUTICALS INTL for Q3 2026.

Managers reporting KINIKSA PHARMACEUTICALS INTL in Q3 2026.
Manager Activity Shares Change % of reported 13F Reported value Tenure
FMR LLC Added 7,487,391 +516,030 0.02% $558,634,260 10 qtrs
BlackRock Inc Added 2,943,674 +204,059 < 0.01% $219,627,516 9 qtrs
BAKER BROS ADVISORS LP Unchanged 2,834,643 0 1.0% $211,492,714 10 qtrs
Rubric Capital Management LP Reduced 2,813,469 -1,186,331 1.97% $209,912,922 10 qtrs
TANG CAPITAL MANAGEMENT LLC Unchanged 2,259,889 0 7.76% $168,610,318 10 qtrs
VANGUARD PORTFOLIO MANAGEMENT LLC Added 2,030,666 +119,331 < 0.01% $151,507,990 3 qtrs
VANGUARD CAPITAL MANAGEMENT LLC Added 1,433,679 +72,839 < 0.01% $106,966,790 3 qtrs
ARROWSTREET CAPITAL LIMITED PARTNERSHIP Added 1,093,930 +136,416 0.03% $81,618,117 10 qtrs
MORGAN STANLEY Reduced 936,373 -74,770 < 0.01% $69,862,871 10 qtrs
STATE STREET CORPORATION Added 926,267 +222,073 < 0.01% $69,108,781 10 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
September 30, 2026
Filed
November 16, 2026
Filing type
13F-HR
Position type
ORD SHS CL A

Voting authority reported

Sole
398,282
Shared
0
None
67,768

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.